Table 1.
Pertinent clinical data in patients with Graves’ disease (GD), with or without thyroid associated opbthalmopathy (TAO), treated with rituximab. Influence on thyroid function and TAO.
| Study and reference number |
Number and sex |
Rituximab dose |
Thyroid State | Initial CAS |
Final CAS |
Side- effects |
Remission- rate |
|---|---|---|---|---|---|---|---|
| El Fassi et al 2007 (42) | 10 F. 2 with TAO | 375 mg/m2 weekly for 4 weeks | Euthyroid | 5 and 6 | 1 and 2 | 5 of 10 | 4 of 10 (a) |
| Salvi et al. 2007 (43) | 7 F; 2 M 7 with TAO | 1 g twice with 2 week interval | 4 hyperthyroid 5 euthyroid | Mean 4.7 | Mean 1.8 | 3 of 9 | NA |
| Heemstra et al. 2008 (44) | 9 F; 4 M 3 with mild TAO | 1 g twice with two week interval | Hyperthyroid | NA | NA | 2 of 13 | 9 of 13 (b) |
| Khanna et al. 2010(59) | 4 F; 2 M All with TAO | 1g twice with 2 week interval | Euthyroid | Mean 5.3 | Mean 1.8 | 3 of 6 | NA |
a
Followup 14–30 months post rituximab therapy
b
Followup 14–30 months post rituximab
F; females
M; males
TAO; thyroid associated ophthalmopathy
CAS; clinical activity score
NA; not applicable